Loading data for JSPR — first visit, this takes a few seconds.

Alerta

Jasper Therapeutics Inc. (JSPR)

NasdaqCM: JSPR · Precio en tiempo real · USD

0.72

+0.00 (0.00%)

Al cierre: Aug 26, 2026, 3:59 PM

0.71

-0.82%

Fuera de horario: 7:30 PM

El precio, las cifras principales y las últimas noticias, en un solo sitio.

0.00% (1D)

Precio de compra	0.5
Capitalización de mercado	23.89M
Ingresos (TTM)	n/a
Beneficio neto (TTM)	-31.77M
	3.03
	-0.93
	n/a
	-0.28
P/B (TTM)	5.93
P/S (TTM)	n/a
Fecha de resultados	Nov 10, 2026

Precio de venta	0.91
Volumen	244,972
Volumen medio (20D)	1,528,741
Abierto	0.71
Anterior Cerrar	0.72
Rango del día	0.70 - 0.72
Rango de 52 semanas	0.32 - 2.98
analista	n/a
Precio objetivo	n/a
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de JSPR

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factors from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with v...

[Leer más]

Industria Biotechnology

Sector Healthcare

IPO Fecha Jan 10, 2020

Empleados 22

Bolsa de Valores NasdaqCM

Símbolo bursátil JSPR

Sitio web https://jaspertx.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Jasper Therapeutics fueron 0, un aumento de undefined% en comparación con 0 del año anterior. Las ganancias fueron -75.8M, un aumento de 6.36%.

Estados financieros

Sorpresa de resultados

Jasper Therapeutics ha publicado sus resultados trimestrales en Aug 14, 2026:

Ingresos de $0 falla las estimaciones por $0, con NaN% Crecimiento interanual.
EPS de -0.23 supera las estimaciones en 0.32, con 86.78% Crecimiento interanual.

Próxima publicación de resultados

Está previsto que Jasper Therapeutics Inc. publique sus resultados el Nov 10, 2026, durante el horario de mercado.
Los analistas proyectan ingresos de ... Actualizar

Noticias

1 semana hace · InvestorsHub

Jasper Therapeutics beats Q2 expectations but shares fall after results

Jasper Therapeutics Inc. (NASDAQ:JSPR) reported better-than-expected second-quarter 2026 results on Monday, although shares of the clinical-stage biotechnology company fell 4.

1 mes hace · BioPharma Dive

Jasper gets a lifeline in merger with immune drugmaker Kira

The acquisition, which involves a concurrent licensing deal with startup Mirador, gives Jasper a chance to rebound from setbacks that have wiped out most of its market value.

2 meses hace · Zacks

Bears are Losing Control Over Jasper Therapeutics (JSPR), Here's Why It's a 'Buy' Now

Jasper Therapeutics (JSPR) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement ...

4 meses hace · Insider Monkey

Evercore ISI Lowers its Price Target on Jasper Therapeutics (JSPR) to $7

Jasper Therapeutics, Inc. (NASDAQ:JSPR) is one of the 8 Most Oversold Penny Stocks to Buy Right Now. On April 1, 2026, Evercore ISI lowered the price target on Jasper Therapeutics, Inc. (NASDAQ:JSPR) ...

5 meses hace · Insider Monkey

Why UBS Started Jasper Therapeutics (JSPR) at Neutral Despite Progress in Briquilimab

Jasper Therapeutics, Inc. (NASDAQ:JSPR) is one of the penny stocks with the potential to rise 1000 percent. UBS initiated coverage of Jasper Therapeutics on March 23, 2026, with a Neutral rating and a...

Página 1 de 2

Jasper Therapeutics Inc. (JSPR)